Simcere Pharmaceutical Group Limited (HKG:2096)

Market Cap	25.35B +17.5%
Revenue (ttm)	8.60B +16.5%
Net Income	1.50B +86.2%
EPS	0.60 +87.9%
Shares Out	2.57B
PE Ratio	16.42
Forward PE	11.43
Dividend	0.21 (2.11%)
Ex-Dividend Date	Jun 17, 2026

Volume	4,728,640
Open	9.87
Previous Close	9.87
Day's Range	9.50 - 9.87
52-Week Range	9.50 - 15.08
Beta	0.64
Analysts	Strong Buy
Price Target	17.83 (+85.15%)
Earnings Date	Aug 20, 2026

About HKG:2096

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Rα; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clini...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 7,038
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2096

Financial Performance

In 2025, HKG:2096's revenue was 7.73 billion, an increase of 16.52% compared to the previous year's 6.64 billion. Earnings were 1.34 billion, an increase of 86.15%.

Financial numbers in CNY

Analyst Summary

According to 7 analysts, the average rating for 2096 stock is "Strong Buy." The 12-month stock price target is $17.83, which is an increase of 85.15% from the latest price.

Price Target

$17.83

(85.15% upside)

Analyst Consensus: Strong Buy